Molecular group:
Cytokines and receptors
Molecule/Cell:
LTbR
Plasmodium strain:
Plasmodium berghei ANKA
pRBC infection titer:
10^4
Mouse genetic background (Con):
C57BL/6
Experimental treatment group (EG):
anti-LTbR
Lethal infection (Con):
yes
Lethal infection (EG):
yes
Pathology (Con):
CM (80%)
Pathology (EG):
No CM
Parasitemia (EG vs Con):
Delayed onset
Additional phenotypes (EG vs Con):
Prolonged survival (~ 2 weeks) only when administered before infection and 4 days p.i. (no protection with a single injection); no neurological symptoms; ↓ whole body parasite burden (PBAluc bioluminescence); ↓ parasite, macrophage and CD8+ T cell accumulation in perfused brains; similar IFN-g production by splenic NK and CD8+ T cells 3 days p.i.; similar MHCII, CD80, CD86 and CD40 expression by splenic conventional DC (cDC); similar proliferation, IFN-g and TNF-a production by parasite-specific splenic CD4+ T cells; ↓ serum TNF-a, IL-6, IFN-g and IL-10 7 days p.i.; similar annexin V staining and intracellular levels of bcl-2 in T cells, macrophages or DCs; expansion of splenic macrophages (CD11b+ Ly6C+) (also in noninfected, anti-LTbR treated mice); similar Ag uptake and processing by cDC and macrophages; similar uptake of GFP-transgenic PbA by macrophages
Refs:
Randall et al., 2008, J Immunol
Hyperlink: